GlaxoSmithKline's Nucala Wins FDA Approval for EGPA By Sam | December 11, 2017 The approval for EGPA is based on results from the pivotal, 52-week, Phase III MIRRA1 study, conducted as a collaboration between GSK and the NIAID, part of the US NIH. Source: BioSpace Posted in BioPharma